IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC. ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Stock
Equities
1541
CNE100006624
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.9 HKD | -0.53% |
|
+1.09% | -50.17% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2023 | 386K 53.43K 418K | Sales 2024 * | 588K 81.46K 637K | Capitalization | 5.18B 717M 5.61B |
|---|---|---|---|---|---|
| Net income 2023 * | - | Net income 2024 * | - | EV / Sales 2023 | 25,574 x |
| Net cash position 2023 | 297M 41.06M 321M | Net cash position 2024 * | 494M 68.37M 534M | EV / Sales 2024 * | 7,965 x |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 145 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 30.46% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.53% | ||
| 1 week | +1.09% | ||
| Current month | -2.10% | ||
| 1 month | -3.25% | ||
| 3 months | -24.75% | ||
| 6 months | -44.81% | ||
| Current year | -50.17% |
1 week
14.04
16.00
1 month
13.5817.70
Current year
13.5830.40
1 year
13.5832.15
3 years
13.5832.15
5 years
13.5832.15
10 years
13.5832.15
| Managers | Title | Age | Since |
|---|---|---|---|
Wen Zhi Tian
CEO | Chief Executive Officer | - | 15-05-31 |
Qi Ying Lu
CTO | Chief Tech/Sci/R&D Officer | - | 22-02-28 |
Song Li
CTO | Chief Tech/Sci/R&D Officer | - | 15-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chi Tat Yeung
BRD | Director/Board Member | 55 | - |
Zhi Hua Yu
BRD | Director/Board Member | 56 | - |
Wen Zhi Tian
CEO | Chief Executive Officer | - | 15-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 14.9 | -0.53% | 193 400 |
| 24-05-08 | 14.98 | +3.88% | 140,800 |
| 24-05-07 | 14.42 | +0.28% | 137,200 |
| 24-05-06 | 14.38 | +2.28% | 139,600 |
| 24-05-03 | 14.06 | -4.61% | 124,400 |
Delayed Quote Hong Kong S.E., May 09, 2024 at 04:08 am EDT
More quotes
ImmuneOnco Biopharmaceuticals Shanghai Inc is a China-based company mainly engaged in research and development of testing biotechnology. The Company's main businesses include the development of biotechnology for the systemic utilization of innate and adaptive immunity, and the development of next-generation tumor immunotherapies, which primarily focus on the adaptive immune system. The Company mainly operates its businesses in the domestic and overseas markets.
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
13.85
CNY
Average target price
15.13
CNY
Spread / Average Target
+9.27%
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -50.17% | 717M | |
| +2.93% | 108B | |
| +8.82% | 105B | |
| +1.80% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B |
- Stock Market
- Equities
- 1541 Stock